Intermagnetics sales boom, profits plateau
Fourth quarter sales by Intermagnetics General rose more than 33% in the quarter ending May 30 to $5.8 million, or 34¢ per diluted share, from $4.4 million, or 26¢ per diluted share, a year earlier. Net sales increased 57% to $59.1 million from $37.7
Fourth quarter sales by Intermagnetics General rose more than 33% in the quarter ending May 30 to $5.8 million, or 34¢ per diluted share, from $4.4 million, or 26¢ per diluted share, a year earlier. Net sales increased 57% to $59.1 million from $37.7 million. Gains were attributed to on-target performance from recently acquired Invivo, a manufacturer of specialty patient monitors.
For fiscal 2004, net income at the Latham, NY, company, excluding acquisition-related charges, was $15.6 million, or 92¢ per diluted share, compared with $15.9 million, or 94¢ per diluted share, excluding one-time items for the previous year. Reported net income for the fiscal year was $14.8 million, or 87¢ per diluted share, compared with $14.9 million, or 88¢ per diluted share in 2003. The first quarter of FY04 was affected by a planned reduction in deliveries of magnet systems to accommodate a strategic enhancement to the company's exclusive supply agreement with Philips Medical Systems. Intermagnetics said overall operations performed at, or slightly above, previously forecasted levels. The year ahead is expected to bring record financial results. The company announced a three-for-two stock split to enhance liquidity of shares.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
